Medically reviewed by Drugs.com. Last updated on Nov 15, 2022.
Applies to the following strengths: 1.75 mg/0.3 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Hypoactive Sexual Desire Disorder
1.75 mg subcutaneously as needed 45 minutes before anticipated sexual activity
- No more than 1 dose should be administered within 24-hour period
- Administering more than 8 doses/month is not recommended
- Hypoactive sexual desire disorder (HSDD) is characterized by low sexual desire that causes marked distress or interpersonal difficulty.
- Acquired HSDD means the patient has previously had no problems with sexual desire.
- Generalized HSDD means the condition occurs regardless of the type of stimulation, situation, or partner.
- This drug is not for the treatment of HSDD in postmenopausal women or in men; it is not indicated to enhance sexual performance.
- This drug should be discontinued if there is no improvement in symptoms after 8 weeks.
Use: For the treatment of acquired, generalized HSDD in premenopausal women not due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.
Renal Dose Adjustments
Mild renal impairment (eGFR 30 to 89 mL/min/1.73 m2): No adjustment recommended
Severe renal impairment (eGFR less than 30 mL/min/1.73 m2): Use with caution
Liver Dose Adjustments
Mild to moderate hepatic impairment (Child-Pugh A and B): No adjustment recommended
Severe hepatic impairment (Child-Pugh C): Use with caution
- Uncontrolled hypertension
- Known cardiovascular disease
Safety and efficacy have not been established in patients younger than 18 years or in postmenopausal women.
Consult WARNINGS section for additional precautions.
Data not available
- Inject subcutaneously in the abdomen or thigh at least 45 minutes prior to sexual activity
- Do not administer more than 1 dose in 24-hour period
- Administering more than 8 doses in a 1-month period is not recommended
- Store below 25C (77F); do not freeze
- Protect from light
- This drug is self-administered via a prefilled auto-injector pen; consult instructions for use for specific administration instructions with illustrations.
- This drug should not be administered more than once in a 24-hour period to minimize the risk of more pronounced blood pressure effects.
- The duration of efficacy after each dose is unknown; the optimal time for drug administration has not been fully characterized and patient experience may guide their use.
- This drug should be discontinued after 8 weeks if there is no improvement in symptoms of hypoactive sexual desire disorder (HSDD).
- Monitor for improvement in symptoms of HSDD
- Monitor for focal hyperpigmentation
- Patients should be instructed to read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
- Patients should understand that transient blood pressure elevations may occur and generally resolve within 12 hours; taking this drug with less than 24 hours between doses may lead to more pronounced blood pressure elevations.
- Patients should be advised that pigmentary changes may occur, and they should contact their healthcare provided if they have changes to their skin.
- Patients should understand that nausea may occur, most commonly with first dose; if nausea is severe or persistent, they should contact their healthcare provider.
- Patients of reproductive potential should be instructed to use effective contraception and should discontinue use if they suspect they are pregnant.
Frequently asked questions
More about bremelanotide
- Check interactions
- Compare alternatives
- Reviews (24)
- Side effects
- During pregnancy
- Drug class: melanocortin receptor agonists
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.